Moderna Inc
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
MRNA$254.19+5.3%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions, except per share data)
| June 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $2,478 | $2,907 |
| Investments | 6,010 | 5,697 |
| Accounts receivable, net | 163 | 892 |
| Inventory | 399 | 202 |
| Prepaid expenses and other current assets | 611 | 627 |
| Total current assets | 9,661 | 10,325 |
| Investments, non-current | 2,326 | 4,677 |
| Property, plant and equipment, net | 2,196 | 1,945 |
| Right-of-use assets, operating leases | 775 | 713 |
| Deferred tax assets | 81 | 81 |
| Other non-current assets | 641 | 685 |
| Total assets | $15,680 | $18,426 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $279 | $520 |
| Accrued liabilities | 1,333 | 1,798 |
| Deferred revenue | 702 | 568 |
| Income taxes payable | 7 | 63 |
| Other current liabilities | 42 | 66 |
| Total current liabilities | 2,363 | 3,015 |
| Deferred revenue, non-current | 95 | 83 |
| Operating lease liabilities, non-current | 668 | 643 |
| Financing lease liabilities, non-current | 576 | 575 |
| Other non-current liabilities | 266 | 256 |
| Total liabilities | 3,968 | 4,572 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 162 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued or outstanding at June 30, 2024 and December 31, 2023 | — | — |
| Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2024 and December 31, 2023; 384 and 382 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 631 | 371 |
| Accumulated other comprehensive loss | (71) | (123) |
| Retained earnings | 11,152 | 13,606 |
| Total stockholders’ equity | 11,712 | 13,854 |
| Total liabilities and stockholders’ equity | $15,680 | $18,426 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.